Adalimumab and myositis: a case report and review of the French and international Pharmacovigilance databases

0

Since the early 2000s, TNFα inhibitors have revolutionized the treatment of inflammatory rheumatologic disease and chronic inflammatory bowel disease such as Crohn’s disease [1,2]. TNFα is a pro-inflammatory cytokine with multiple pleiotropic effects including apoptosis, cellular proliferation and pro-inflammatory cytokines production [3]. It has been implicated in various auto-immune diseases. Anti-TNFα therapies have demonstrated their consistent and remarkable efficacy in controlling signs and symptoms, with a favorable safety profile [4].

Read More...

Leave A Reply